Covid-19 or not, I rate the GSK share price as a strong buy right now

Will the GSK share price be boosted by Covid-19 research? Here’s why I’d buy today as a long-term defensive investment, either way.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in these troubled times seems to be about looking for top recovery stocks that are oversold in the Covid-19 crisis. Or, fearing a second dip in the 2020 stock market crash, seeking defensive holdings. I place GlaxoSmithKline (LSE: GSK) firmly in the second category, even though the GSK share price is down 11% so far in 2020.

Some investors might be buying GlaxoSmithKline shares for the hope of profits arising from Covid-19 research. But I think that would be a mistake. A number of the world’s big pharma companies have pledged to provide any vaccines they might come up with on a no-profit basis. So if that’s your target, I’d suggest going for one of the smaller biotech firms instead. Like Synairgen, whose share price has five-bagged in the past month. I really can’t see the GSK share price doing that.

We did have news of GSK’s vaccine research on Wednesday. It related to a vaccine candidate and its potential supply to the UK government. It uses “Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system“.

I think I, partly, understand what that means. But the crucial information comes in two parts. One is that the companies have agreed to supply up to 60 million doses in the UK. The other is that “Both companies are committed to making their COVID-19 vaccine candidate affordable and available globally“.

GSK share price dip

If you’re after profits from GlaxoSmithKline, I suggest you look to the firm’s wider drugs portfolio and its long-term profitability. We had news on that score Wednesday too, with mixed results over the first and second quarters of the year. Q2 saw a 3% drop in turnover (at constant exchange rates), leading to a 21% fall in adjusted operating profit. Looking to the whole of the first half, we see an 8% rise in turnover and a 2% upwards blip in adjusted operating profit. The GSK share price dipped a couple of percent on the day.

But, I’m really not too interested in quarter-by-quarter results. My attention is always on a drugs company’s development pipeline, which is where long-term profits come from. The company spoke of “continued strengthening of the biopharma pipeline which now contains 35 medicines and 15 vaccines; over 75% of pipeline assets are focused on immunology“.

As well as immunology, GlaxoSmithKline is big in HIV, oncology, and respiratory research. In short, it has its portfolio spread across the bulk of ailments afflicting the world’s increasingly affluent inhabitants.

Valuation

On the current GSK share price, we’re looking at forecast P/E multiples of 13 to 13.5. For a company with predicted dividend yields of around 5%, I’d consider that good value. And for a firm with the long-term defensive nature of GlaxoSmithKline, I rate it as a strong buy.

The dividend has been flat for a number of years now as GSK has pursued its development pipeline turnaround. But I see it as safe, and I’d be perfectly happy with the current yield until we see a resumption of earnings growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »